Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6794489 | PALATIN TECHNOLOGIES | Compositions and methods for treatment of sexual dysfunction |
Jun, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9352013 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(10 years from now) | |
US9700592 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(10 years from now) | |
US10286034 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(10 years from now) | |
US11590209 | PALATIN TECHNOLOGIES | Use of bremelanotide in patients with controlled hypertension |
Apr, 2041
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 21, 2024 |
NCE-1 date: 2023-06-22
Market Authorisation Date: 21 June, 2019
Treatment: Treatment of hypoactive sexual desire disorder (hsdd); Treating acquired, generalized hypoactive sexual desire disorder (hsdd) in a premenopausal female patient with controlled hypertension by injecti...
Dosage: SOLUTION;SUBCUTANEOUS
30
United States
8
European Union
6
Canada
6
Japan
6
Australia
5
Mexico
4
China
3
Korea, Republic of
3
Brazil
2
Hong Kong
2
Denmark
2
Spain
2
New Zealand
2
South Africa
1
Georgia
1
Poland
1
Philippines
1
Ukraine
1
Germany
1
EA
1
Austria
1
Portugal
1
Singapore
1
Israel
1
Malaysia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic